Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?

Muhamed Baljevic; Jae H. Park; Eytan Stein; Dan Douer; Jessica K. Altman; Martin S. Tallman

doi:10.1016/j.hoc.2011.10.002

Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?

Muhamed Baljevic, Jae H. Park, Eytan Stein, Dan Douer, Jessica K. Altman, Martin S. Tallman^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

Original language	English (US)
Pages (from-to)	1215-1233
Number of pages	19
Journal	Hematology/Oncology Clinics of North America
Volume	25
Issue number	6
DOIs	https://doi.org/10.1016/j.hoc.2011.10.002
State	Published - Dec 2011

Keywords

Acute promyelocytic leukemia
All-trans retinoic acid
Arsenic trioxide
Cure
Targeted therapies

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2011.10.002

Cite this

@article{cd05bce252ac47ef9f8e72a544dab5fc,

title = "Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?",

abstract = "The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.",

keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, Arsenic trioxide, Cure, Targeted therapies",

author = "Muhamed Baljevic and Park, {Jae H.} and Eytan Stein and Dan Douer and Altman, {Jessica K.} and Tallman, {Martin S.}",

year = "2011",

month = dec,

doi = "10.1016/j.hoc.2011.10.002",

language = "English (US)",

volume = "25",

pages = "1215--1233",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - Curing All Patients with Acute Promyelocytic Leukemia

T2 - Are We There Yet?

AU - Baljevic, Muhamed

AU - Park, Jae H.

AU - Stein, Eytan

AU - Douer, Dan

AU - Altman, Jessica K.

AU - Tallman, Martin S.

PY - 2011/12

Y1 - 2011/12

N2 - The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

AB - The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - Arsenic trioxide

KW - Cure

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=81255177098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255177098&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2011.10.002

DO - 10.1016/j.hoc.2011.10.002

M3 - Review article

C2 - 22093584

AN - SCOPUS:81255177098

SN - 0889-8588

VL - 25

SP - 1215

EP - 1233

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 6

ER -

Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this